Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $191.00M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.23M
Average 0.38M
PRLD Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 46.0% from a year ago
Cash & equivalents stood at $21.76M at the end of Q1 FY2026, down 46.0% from a year earlier and down 38.3% from the prior quarter. Over 3 fiscal years it compounded at +4.8% a year.
Context
- Cash & equivalents amounted to 18.2% of total assets at the end of Q1 FY2026, down 10.3 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -46.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 35.26M USD
- Year-over-year change
- +182.6%
- 4-year CAGR
- +2.6%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 35.26M | +182.6% |
| FY2024 | 2024-12-31 | 12.47M | -50.7% |
| FY2023 | 2023-12-31 | 25.29M | -17.4% |
| FY2022 | 2022-12-31 | 30.61M | -3.8% |
| FY2021 | 2021-12-31 | 31.83M | — |
Cash & Equivalents vs competitors
How PRLD compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -46.0% is the 9th highest of 11, against a peer median of +17.4%.
- Cash & equivalents amounts to 18.2% of total assets for PRLD, versus a peer median of 26.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | €99.27M EUR | +2.8% | +4.6% | 39.9% | |
| Mar 2026 | $88.91M USD | +45.7% | +15.7% | 40.0% | |
| Mar 2026 | $80.89M USD | +50.4% | +1.8% | 59.9% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $58.69M USD | +113.8% | +48.2% | 40.2% |
| Mar 2026 | $47.32M USD | +31.9% | +21.0% | 0.0% | |
| Mar 2026 | $34.93M USD | -42.0% | -9.8% | 11.1% | |
| Mar 2026 | $28.37M USD | +54.6% | +20.6% | 28.2% | |
| Mar 2026 | $24.99M USD | -80.0% | +6.4% | 25.0% | |
| Mar 2026 | $21.76M USD | -46.0% | +4.8% | 18.2% | |
| Mar 2026 | $12.06M USD | -59.0% | -40.4% | 8.1% | |
| Mar 2026 | $7.24M USD | -43.3% | -55.9% | 11.3% | |
| Peer median (excluding PRLD) | — | +17.4% | +5.5% | 26.6% | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 31.83M | 30.61M | 25.29M | 12.47M | 35.26M |
| Short-term Investments | 259.41M | 171.12M | 207.64M | 121.14M | 67.96M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 2.65M | 2.65M | 2.28M | 2.48M |
| Total Current Assets | 295.12M | 204.38M | 235.59M | 135.9M | 105.69M |
| Property, Plant & Equipment (Net) | 5.64M | 6.7M | 37.74M | 35.47M | 32.28M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 4.35M | 9.42M | 4.34M | 4.15M | 3.35M |
| Total Non-current Assets | 9.98M | 16.12M | 42.08M | 39.62M | 35.62M |
| Total Assets | 305.1M | 220.5M | 277.67M | 175.52M | 141.32M |
| Account Payables | 7.84M | 6.78M | 4.58M | 7.73M | 3.98M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 33.73M |
| Other Current Liabilities | 5.01M | 6.21M | 6.61M | 9.79M | 5.4M |
| Total Current Liabilities | 19.2M | 21.7M | 21.83M | 25.64M | 52.99M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 1.8M |
| Other Non-current Liabilities | 0 | 3.36M | 3.34M | 3.09M | 2.84M |
| Total Non-current Liabilities | 0 | 3.36M | 18.75M | 18.42M | 19.68M |
| Total Liabilities | 19.2M | 25.06M | 40.58M | 44.06M | 72.68M |
| Common Stock | 5K | 5K | 5K | 5K | 5K |
| Retained Earnings | (219.12M) | (334.56M) | (456.39M) | (583.56M) | (683.06M) |
| Accumulated OCI | (711K) | (1.69M) | 223K | 35K | 8K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 285.9M | 195.44M | 237.09M | 131.46M | 68.64M |
| Total Debt | 1.74M | 1.83M | 16.89M | 18.03M | 17.79M |
| Net Debt | (30.09M) | (28.77M) | (8.4M) | 5.55M | (17.47M) |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.